Session 12: Adjuvant systemic treatment for the individual patient II: Cytotoxic chemotherapy and targeted agents

Chairs: Ian Smith (United Kingdom), Sybille Loibl (Germany)

  • Tailoring the chemotherapy regimen in patients with triple negative subtypes (Eric Winer, USA)
  • Defining optimal duration and predicting benefit from chemo-therapy in patients with luminal-like subtypes (Angelo Di Leo, Italy)
  • Targeting HER2 in 2015 (Martine Piccart-Gebhart, Belgium)
  • Long term side effects of adjuvant chemotherapy in patients with early breast cancer (Antonio Wolff, USA)
  • Discussion